Abstract
γ-Hydroxybutyrate (GHB) is an emerging drug of abuse with multiple mechanisms of action. This study is part of an effort to examine the role of GHB, GABAA, and GABAB receptors in the discriminative stimulus (DS) effects of GHB. In pigeons trained to discriminate 100 mg/kg GHB from saline, GHB and its precursors γ-butyrolactone and 1,4-butanediol produced 80 to 100% GHB-appropriate responding, whereas other compounds such as morphine, naltrexone, cocaine, and haloperidol produced no more than 34%. Compounds interacting with GABA receptors produced different maximal levels of GHB-appropriate responding. For example, the GABAA agonist muscimol produced 3%; the GABAA-positive modulators diazepam, pentobarbital, and ethanol, and the GABAB agonist baclofen produced levels ranging from 54 to 73%; and the benzodiazepine antagonist flumazenil and inverse agonist Ro 15-4513 (ethyl 8-azido-6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-α]-[1,4]-benzodiazepine-3-carboxylate) both produced 96%. The putative GHB receptor antagonist (2E)-(5-hydroxy-5,7,8,9-tetrahydro-6H-benzo[a][7]annulen-6-ylidene ethanoic acid (NCS-382) produced 70% GHB-appropriate responding. The GABAB antagonist (3-aminopropyl)(diethoxymethyl)phosphinic acid (CGP 35348) completely blocked the GHB-like DS effects of NCS-382 and baclofen at a dose of 56 mg/kg. CGP 35348 also blocked the DS effects of GHB, but incompletely and only at a dose of 560 mg/kg. Together, these results are consistent with a role for diazepam-sensitive and -insensitive GABAA and GABAB receptors in the DS effects of GHB. Together with previous findings, the present results suggest that diazepam-insensitive GABAA receptors are more prominently involved in the DS effects of GHB in pigeons than in rats, whereas GABAB receptors are less prominently involved. Exploring the role of GHB receptors with NCS-382 is hampered by its GABAB receptor-mediated, GHB-like agonist activity.
Footnotes
-
This study was supported by U.S. Public Health Service Grants DA14986 and DA15692. C.P.F. is supported by a Research Career Award (DA00211). Portions of these studies were presented in preliminary form at the 2002 meeting of the Society for Neuroscience in Orlando, FL and at the Experimental Biology 2003 meeting in San Diego, CA.
-
DOI: 10.1124/jpet.103.056093.
-
ABBREVIATIONS: GHB, γ-hydroxybutyrate; NCS-382, (2E)-(5-hydroxy-5,7,8,9-tetrahydro-6H-benzo[a][7]annulen-6-ylidene ethanoic acid; CGP 35348, (3-aminopropyl) (diethoxymethyl)phosphinic acid; DS, discriminative stimulus; 1,4-BDL, 1,4-butanediol; GBL, γ-butyrolactone; CL, confidence limits; Ro 15-4513, ethyl 8-azido-6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-α]-[1,4]-benzodiazepine-3-carboxylate.
- Received June 25, 2003.
- Accepted November 25, 2003.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|